Fundamentals of Cancer Detection, Treatment, and Prevention. Surya K. De

Freedman, A. (2012). Follicular lymphoma: 2012 update on diagnosis and management. Am. J. Hematol. 87 (10): 988–995. https://doi.org/10.1002/ajh.23313. PMID: 23001911.

      25 25 Madan, V., Lear, J.T., and Szeimies, R.M. (2010). Non‐melanoma skin cancer. Lancet 375 (9715): 673–685. https://doi.org/10.1016/S0140-6736(09)61196-X. PMID: 20171403.

      26 26 Waldmann, T.A. (2003). Immunotherapy: past, present and future. Nat. Med. 9 (3): 269–277. https://doi.org/10.1038/nm0303-269. PMID: 12612576.

      27 27 Gulati, A.P. and Domchek, S.M. (2008). The clinical management of BRCA1 and BRCA2 mutation carriers. Curr. Oncol. Rep. 10 (1): 47–53. https://doi.org/10.1007/s11912-008-0008-9. PMID: 18366960.

      28 28 Vanneman, M. and Dranoff, G. (2012). Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12 (4): 237–251.

      29 29 Chandran, R., Hakki, M., and Spurgeon, S. (2012). Infections in leukemia. In: Sepsis: An Ongoing and Significant Challenge (ed. L. Azevedo). London, UK: IntechOpen.

      30 30 Carter, Y., Sippel, R.S., and Chen, H. (2014). Hypothyroidism after a cancer diagnosis: etiology, diagnosis, complications, and management. Oncologist 19 (1): 34–43.

      31 31 Moen, I. and Stuhr, L.E. (2012). Hyperbaric oxygen therapy and cancer – a review. Target. Oncol. 7 (4): 233–242.

      32 32 Artandi, S.E. and Depinho, R.A. (2010). Telomeres and telomerase in cancer. Carcinogenesis 31 (1): 9–18.

      33 33 Wheeler, D.L., Dunn, E.F., and Harari, P.M. (2010). Understanding resistance to EGFR inhibitors‐impact on future treatment strategies. Nat. Rev. Clin. Oncol. 7 (9): 493–507.

      34 34 DeBaradinis, R., Lum, J.J., Hatzivassiliou, G., and Thompson, C.B. (2008). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7 (1): 11–20. https://doi.org/10.1016/j.cmet.2007.10.002. PMID: 18177721.

      35 35 Nio, K., Yamashita, T., and Kaneko, S. (2017). The evolving concept of liver cancer stem cells. Mol. Cancer 16 (1): 4.

      36 36 Plüddemann, A., Heneghan, C., Thompson, M. et al. (2011). Dermoscopy for the diagnosis of melanoma: primary care diagnostic technology update. Br. J. Gen. Pract. 61 (587): 416–417.

      37 37 Poggi, M.M., Danforth, D.N., Sciuto, L.C. et al. (2003). Eighteen‐year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer 98 (4): 697–702.

      38 38 Stubbe, C.E. and Valero, M. (2013). Complementary strategies for the management of radiation therapy side effects. J. Adv. Pract. Oncol. 4 (4): 219–231.

      39 39 Karczmarek‐borowska, B. and Sałek‐zań, A. (2015). Hepatotoxicity of molecular targeted therapy. Contemp. Oncol. (Pozn). 19 (2): 87–92.

      40 40 Fakih, M. and Vincent, M. (2010). Adverse events associated with anti‐EGFR therapies for the treatment of metastatic colorectal cancer. Curr. Oncol. 17 (Suppl 1): S18–S30.

      41 41 Parker, W.H., Jacoby, V., Shoupe, D., and Rocca, W. (2009). Effect of bilateral oophorectomy on women's long‐term health. Womens Health (Lond). 5 (5): 565–576.

      42 42 Hoffner, B. and Zitella, L.J. (2018). Managing side effects of cancer patients treated with immunotherapy. J. Adv. Pract. Oncol. 9 (3): 287–292.

      43 43 Baguley, B.J., Bolam, K.A., Wright, O.R.L., and Skinner, T.L. (2017). The effect of nutrition therapy and exercise on cancer‐related fatigue and quality of life in men with prostate cancer: a systematic review. Nutrients 9 (9): 1003.

      44 44 Ernst, E. (2009). Complementary and alternative medicine (CAM) and cancer: the kind face of complementary medicine. Int. J. Surg. 7 (6): 499–500.

      45 45 Bridges, J., Hughes, J., Farrington, N., and Richardson, A. (2015). Cancer treatment decision‐making processes for older patients with complex needs: a qualitative study. BMJ Open 5 (12): e009674.

      46 46 Ringer, D.P. and Schniper, L.E. (2001). Principles of cancer biology. In: Clinical Oncology (ed. R.E. Lenhard, R.T. Osteen and T. Gansler), 25–30. Atlanta, GA: American Cancer Society.

      47 47 Anderson, M.K. and Matey, L. (2019). Overview of cancer and cancer treatment. In: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (ed. M.M. Olsen, K.B. LeFebvre and K.J. Brassil), 25–50. Pittsburgh, PA: Oncology Nursing Society.

      48 48 Abshire, D. and Lang, M.K. (2018). The evolution of radiation therapy in treating cancer. Semin. Oncol. Nurs. 34 (2): 151–157.

      49 49 Drapek, L. (2017). Radiation therapy. In: Mosby's Oncology Nurse Advisor, 2e (ed. S. Newton, M. Hickey and J. Brant), 168–171. St Louis, MO: Elsevier.

      50 50 Forshaw, K., Hall, A.E., Boyes, A.W. et al. (2017). Patients' experiences of preparation for radiation therapy: a qualitative study. Oncol. Nurs. Forum 44 (1): E1–E9.

      51 51 Beaud, H., Tremblay, A.R., Chan, P.T.K. et al. (2019). Sperm DNA damage in cancer patients. Adv. Exp. Med. Biol. 1166: 189–203.

      52 52 Allessandrini, L., Perin, T., Kadare, S. et al. (2018). Cancer targeted therapy strategy: the pathologist's perspectives. Curr. Cancer Drug Targets 18 (5): 410–420.

      53 53 Brown, V.T. (2019). Targeted therapy. In: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (ed. M.M. Olsen, K.B. LeFebvre and K.J. Brassil), 103–139. Pittsburgh, PA: Oncology Nursing Society.

      54 54 Comoglio, P.M., Trusolino, L., and Boccaccio, C. (2018). Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nat. Rev. Cancer 18 (6): 341–358.

      55 55 Cully, M. (2017). Targeted therapies: strategies for mature T cell cancers. Nat. Rev. Cancer 18 (1): 3.

      56 56 Rosinol, L., Oriol, A., Teruel, A.I. et al. (2017). Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: A PETHEMA/GEM trial. Leukemia 31 (9): 1922–1927.

      57 57 Von Minckwitz, G., Huang, C.S., Mano, M.S. et al. (2019). Trastuzumab emtansine for residual invasive HER2‐positive breast cancer. N. Engl. J. Med. 380 (7): 617–628.

      58 58 Xu, M.J., Johnson, D.E., and Grandis, J.R. (2017). EGFR‐targeted therapies in the post‐genomic era. Cancer Metastasis Rev. 36 (3): 463–473.

      59 59 DeMaria, P.J. and Bilusic, M. (2019). Cancer vaccines. Hematol. Oncol. Clin. North Am. 33 (2): 199–214.

      60 60 DeSelm, C.J., Tano, Z.E., Varghese, A.M. et al. (2017). CAR T‐cell therapy for pancreatic cancer. J. Surg. Oncol. 16 (1): 63–74.

      61 61 Gatti‐Mays, M.E., Redman, J.M., Collins, J.M. et al. (2017). Cancer vaccines: enhanced immunogenic modulation through therapeutic combinations. Hum. Vaccin. Immunother. 13 (11): 2561–2574.

      62 62 Hafeez, U., Gan, H.K., and Scott, A.M. (2018). Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. Curr. Opin. Pharmacol. 41: 114–121.

      63 63 Maeng, H., Terabe, M., and Berzofsky, J.A. (2018). Cancer vaccines: translation from mice to human clinical trials. Curr. Opin. Immunol. 51: 111–122.

      64 64 Myers, D.R., Wheeler, B., and Roose, J.P. (2019). mTOR and other effector kinase signals that impact T cell function and activity. Immunol. Rev. 291 (1): 134–153.

      65 65 Burstein, H.J., Lacchetti, C., Anderson, H. et al. (2019). Adjuvant endocrine therapy for Women with hormone receptor‐positive breast cancer: ASCO clinical practice guideline focused update. J. Clin. Oncol. 37 (5): 423–438.

      66 66 Szabo, R.A., Marino, J.L., and Hickey, M. (2019). Managing menopausal symptoms after cancer. Climacteric 22 (6): 572–578.

      67 67 Fong, P.C., Boss, D.S., Yap, T.A. et al. (2009). Inhibition of